Edgewise Therapeutics, Inc. (EWTX) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$143.82M | -31.9% |
| 2024 | -$109.03M | -18.6% |
| 2023 | -$91.95M | -74.7% |
| 2022 | -$52.63M | -57.1% |
| 2021 | -$33.51M | -129.0% |
| 2020 | -$14.63M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$143.82M | -31.9% |
| 2024 | -$109.03M | -18.6% |
| 2023 | -$91.95M | -74.7% |
| 2022 | -$52.63M | -57.1% |
| 2021 | -$33.51M | -129.0% |
| 2020 | -$14.63M | — |